Catalog No.
Product Name
Application
Product Information
Citations
-
mTOR Inhibitor
mTOR inhibitor-18 is a selective inhibitor of the mechanistic target of rapamycin (mTOR). It exhibits significant activity in modulating intracellular signaling pathways associated with cell growth, proliferation, and survival. This compound is particularly useful in researching various conditions, including cancer, immune disorders, cardiovascular diseases, viral infections, inflammation, and metabolic or endocrine function disorders. Its role in neurological research further highlights its versatility as a critical tool in understanding mTOR-related biological processes. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-6 is a potent dual inhibitor targeting the phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) pathways. This compound demonstrates enhanced stability in artificial gastric fluids compared to other PI3K/mTOR inhibitors. At a concentration of 10 μM, PI3K/mTOR Inhibitor-6 effectively suppresses the PI3K/Akt/mTOR signaling pathway, highlighting its potential for cancer research applications. -
mTOR Inhibitor
P-2281 is an mTOR inhibitor that exhibits significant anticancer and anti-inflammatory properties. It effectively inhibits mTOR activity in colon cancer cells and suppresses Dextran sulfate sodium salt (DSS)-induced colitis by modulating T cell function. P-2281 has demonstrated efficacy in murine models of human colitis, making it a valuable tool for research into cancer therapies and inflammatory bowel diseases. -
PI3K inhibitor
PI-540 is a bicyclic thienopyrimidine derivative that functions as an orally active inhibitor of phosphoinositide 3-kinases (PI3K). Demonstrating potent anti-cancer cell proliferation activity, PI-540 selectively inhibits various PI3K isoforms with IC50 values of 10 nM for P110α, 3510 nM for P110β, 410 nM for P110δ, and 33110 nM for P110γ. In addition to its PI3K inhibition, PI-540 also targets mTOR and DNA-PK, with IC50 values of 61 nM and 525 nM, respectively, making it a valuable tool for cancer research and therapeutic development. -
PI3K/mTOR Inhibitor
CC-M-1 is a potent and selective inhibitor of the PI3K/mTOR signaling pathway, targeting PI3Kα/β/γ/δ and mTOR with IC50 values of 0.68, 1.02, 1.03, 8.03, and 15 nM, respectively. This compound demonstrates significant inhibition of proliferation in colorectal cancer cell lines, including HCT-116 (IC50 = 0.38 μM) and HT-29 (IC50 = 1.70 μM). CC-M-1 serves as a valuable tool for researchers investigating colorectal cancer (CRC) therapeutic strategies and the underlying mechanisms of tumorigenesis. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-13 is a potent, orally active dual inhibitor targeting phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). This compound demonstrates significant biological activity against various pathologies, including solid tumors, sexual diseases, and idiopathic pulmonary fibrosis (IPF). It serves as a valuable tool for cancer research and therapeutic development related to these conditions. -
mTOR Inhibitor
mTOR inhibitor-13 is a selective inhibitor of mammalian target of rapamycin (mTOR) with an IC50 value of 0.29 nM, demonstrating potent inhibition. Additionally, this compound exhibits activity against PI3K-α with an IC50 of 119 nM. It is primarily utilized in research applications related to cancer, metabolic disorders, and cellular growth regulation, making it a valuable tool for investigating mTOR-mediated pathways. -
mTOR Inhibitor
mTOR inhibitor-17 is a selective inhibitor of the mechanistic target of rapamycin (mTOR), exhibiting an IC50 of 0.68 nM. This compound effectively inhibits cell proliferation in LNCaP prostate cancer cells with an IC50 of 40 nM. It is utilized in research to investigate the role of mTOR signaling in cancer metabolism and therapy. -
mTORC1 Inhibitor
mTORC1-IN-2 is an inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1). This compound functions by upregulating the expression of TSC2-P while concurrently inhibiting mTORC1 signaling. It exhibits vasodilatory effects and offers protection against myocardial hypoxic injury, making it a valuable tool for research in cardiovascular and metabolic disorders. Its impact on mTORC1 signaling pathways underscores its potential in studies related to cellular growth, proliferation, and survival. -
mTOR Inhibitor
mTOR inhibitor-24 (compound 9d) is a potent mTOR inhibitor, exhibiting an IC50 of 0.34 nM against mTOR and 324 nM against PI3K-α. This compound effectively inhibits the proliferation of LNCaP cells with an IC50 of 180 nM. It serves as a valuable tool for research in cancer biology and therapeutic exploration targeting the mTOR signaling pathway. -
mTOR Inhibitor
PF-06465603 is a potent and selective ATP-competitive inhibitor targeting the mTOR pathway. This compound serves as a valuable research tool for studying the regulation of cell growth, proliferation, and survival through mTOR signaling. As a metabolite of PF-04691502, PF-06465603 features a terminal carboxylic acid structure, further facilitating investigations into its biological activity and therapeutic potential in various diseases, including cancer and metabolic disorders. -
mTOR Inhibitor
mTOR inhibitor-16 (Compound 9f) is a selective inhibitor of the mechanistic target of rapamycin (mTOR). It demonstrates potent inhibitory activity against mTOR and PI3K-α, with IC50 values of 1.25 nM and 82 nM, respectively. This compound effectively inhibits the proliferation of LNCaP prostate cancer cells, with an IC50 of 140 nM, making it a valuable tool for cancer research and studies involving the mTOR signaling pathway. -
mTOR-DEPTOR Inhibitor
NSC126405 is an mTOR-DEPTOR inhibitor that disrupts the interaction between mTOR and DEPTOR, leading to enhanced cytotoxicity in multiple myeloma cells. This compound serves as a valuable tool in cancer research, allowing for the exploration of mTOR signaling pathways and potential therapeutic strategies in hematological malignancies. -
PI3K/mTOR Inhibitor
WJD008 is a potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), specifically targeting PI3K α and mTOR kinase activities. It exhibits significant antiproliferative and anticlonogenic effects in tumor cells, particularly those with PIK3CA mutations. By disrupting the insulin-like growth factor-I-activated PI3K-Akt-mTOR signaling pathway, WJD008 holds promise for advancing cancer research and therapeutic strategies. -
mTOR Inhibitor
mTOR inhibitor-10 (Compound 9c) is a selective inhibitor targeting the mechanistic target of rapamycin (mTOR). This compound effectively inhibits both mTOR and PI3K-α, demonstrating IC50 values of 0.7 nM and 825 nM, respectively. mTOR inhibitor-10 exhibits significant anti-proliferative activity against LNCaP cancer cells, with an IC50 value of 87 nM, making it a valuable tool for research in cancer biology and therapeutic applications. -
PI3K Inhibitor
PI3K-IN-30 is a selective inhibitor of phosphoinositide 3-kinases (PI3Ks), demonstrating potent inhibition with IC50 values of 5.1 nM for PI3Kα, 136 nM for PI3Kβ, 30.7 nM for PI3Kγ, and 8.9 nM for PI3Kδ. This compound is suitable for studies investigating PI3K signaling pathways and their implications in cancer and other diseases. Its high specificity and potency make it a valuable tool for biochemical and cellular research focused on PI3K-related mechanisms. -
PI3Kδ Inhibitor
Roginolisib is a selective PI3Kδ inhibitor that exhibits potent activity with an IC50 of 145 nM. This compound demonstrates high selectivity against a broad panel of 278 additional kinases, making it a valuable tool for research in cell signaling pathways. Its application in studies targeting immune responses and cancer biology highlights the importance of PI3Kδ modulation in therapeutic development. -
PI3Kγ Inhibitor
PI3Kγ inhibitor AZ2 selectively targets phosphoinositide 3-kinase gamma (PI3Kγ) with a pIC50 value of 9.3, indicating potent inhibition. This compound is valuable for investigating the role of PI3Kγ in inflammatory and immune diseases, providing insights into potential therapeutic applications. Its specificity makes it a useful tool in biochemical and pharmacological studies related to immune regulation. -
Pan-PI3Ks Ihibitor
AMG 511 is a potent pan-inhibitor of class I phosphoinositide 3-kinases (PI3Ks), demonstrating inhibitory constants (Kis) of 4 nM, 6 nM, 2 nM, and 1 nM for PI3Kα, β, δ, and γ, respectively. This compound effectively suppresses PI3K signaling, as evidenced by a decrease in phosphorylated Akt (Ser473). AMG 511 has shown significant anti-tumor activity in mouse models of glioblastoma, making it a valuable tool for cancer research and therapeutic development. -
PI3K Inhibitor
Duvelisib (R enantiomer) is a selective inhibitor of phosphoinositide 3-kinase (PI3K), targeting the delta and gamma isoforms. It exhibits antitumor activity by inhibiting cell proliferation and promoting apoptosis in various cancer models. This compound is primarily utilized in research focused on cancer treatment, immune response modulation, and signaling pathway analysis. -
PI3Kα Inhibitor
PF-06843195 is a highly selective inhibitor of the PI3Kα isoform, exhibiting an IC50 of 18 nM in Rat1 fibroblasts. With kinase inhibition constants (Kis) of less than 0.018 nM and 0.28 nM for PI3Kα and PI3Kδ respectively, this compound effectively suppresses the PI3K/mTOR signaling pathway. PF-06843195 demonstrates significant antitumor efficacy, making it a valuable tool for research applications targeting cancer biology and therapeutic development. -
PI3KC2α Inhibitor
MIPS-21335 is a selective inhibitor of PI3KC2α, exhibiting an IC50 value of 7 nM. Additionally, it demonstrates inhibition of PI3KC2β, p110α, p110β, and p110δ, with corresponding IC50 values of 43, 140, 386, and 742 nM. MIPS-21335 exhibits significant antithrombotic effects and is valuable for research into cardiovascular and metabolic diseases, including thrombosis and hyperlipidemia. -
PI3Kγδ Inhibitor
AZD8154 is a selective dual inhibitor of the PI3Kγ and PI3Kδ isoforms. By effectively suppressing the activation of these signaling pathways, AZD8154 demonstrates potential in modulating inflammatory responses. This reagent is suitable for research in inflammation and immunology, particularly in studies related to asthma and other related conditions. -
PI3K Inhibitor
PIT-1 is a selective inhibitor of phosphatidylinositol 3,4,5-trisphosphate (PIP3) that targets the PI3K/Akt signaling pathway. By inhibiting PIP3, PIT-1 effectively disrupts cancer cell survival and promotes apoptosis. This compound demonstrates significant antitumor activity in vivo, making it suitable for investigations into cancer therapeutics and signaling pathways involved in oncogenesis. -
PI3Kδ Inhibitor
Leniolisib phosphate is a potent and selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) pathway. This compound exhibits significant biological activity in modulating immune responses, making it a valuable tool for research in immunodeficiency disorders. Its mechanism of action underscores its potential in therapeutic applications targeting underlying immunological defects. -
PI3K Inhibitor
PI3K-IN-31 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), displaying IC50 values of 3.7 nM for PI3Kα, 74 nM for PI3Kβ, 14.6 nM for PI3Kγ, and 9.9 nM for PI3Kδ. Its selective inhibition of these kinases correlates with significant anticancer activity, making it a valuable tool in cancer research. Applications for PI3K-IN-31 include studying the PI3K signaling pathway and evaluating its role in tumorigenesis and therapeutic resistance. -
PI3K
PQR514 is a potent inhibitor of phosphoinositide 3-kinase (PI3K), demonstrating significant anticancer activity. This compound effectively inhibits cancer cell proliferation and exhibits substantial antitumor effects in the OVCAR-3 xenograft model, with required concentrations notably lower than those of other PI3K inhibitors. PQR514 features favorable pharmacokinetic properties and minimal brain penetration, positioning it as an optimized candidate for targeting systemic tumors in cancer research applications. -
PI3Kα Inhibitor
(S)-PI3Kα-IN-4 is a highly selective inhibitor of the phosphoinositide 3-kinase alpha (PI3Kα) isoform, demonstrating an IC50 value of 2.3 nM. This compound exhibits significant selectivity, with 38.3-fold preference for PI3Kα over PI3Kβ, and more than 4-fold selectivity compared to PI3Kδ and PI3Kγ. (S)-PI3Kα-IN-4 is suitable for research applications focusing on cancer biology, particularly in studies aimed at understanding the role of PI3Kα in tumorigenesis and therapeutic resistance. -
PI3K Inhibitor
Vulolisib is a potent, orally active inhibitor of phosphatidylinositol 3-kinase (PI3K), demonstrating IC50 values of 0.2 nM for PI3Kα, 168 nM for PI3Kβ, 90 nM for PI3Kγ, and 49 nM for PI3Kδ. This compound exhibits significant antiproliferative and antineoplastic properties, making it a valuable tool for cancer research. Its selective inhibition of PI3K isoforms facilitates investigations into the role of PI3K signaling in various malignancies. -
PI3Kδ/γ Inhibitor
PI3Kδ/γ-IN-1 is a selective inhibitor targeting phosphoinositide 3-kinase delta (PI3Kδ) and gamma (PI3Kγ), demonstrating high potency in inhibiting their activity. This compound plays a pivotal role in the study of hematological malignancies, facilitating research into the underlying molecular mechanisms and potential therapeutic approaches for conditions such as leukemia and lymphoma. Its specificity for PI3Kδ and PI3Kγ makes it an invaluable tool for investigating the contributions of these isoforms in cancer biology. -
PI3Kγ Inhibitor
NVS-PI3-4 is a selective inhibitor of PI3Kγ, playing a crucial role in modulating the PI3K signaling pathway. This compound demonstrates significant inhibitory activity, making it a valuable tool for investigating the mechanisms underlying allergies, inflammatory disorders, and various cancer types. Researchers can utilize NVS-PI3-4 to explore therapeutic strategies aimed at targeting PI3Kγ-related pathways in relevant disease models. -
PI3Kα Inhibitor
Benzoin is a potent inhibitor of the phosphoinositide 3-kinase alpha (PI3Kα) signaling pathway, known for its potential anticancer effects. This compound has been shown to effectively impede the growth of the colon cancer cell line HCT-116, making it a valuable tool for cancer research. Its application in studying PI3Kα-mediated processes provides insights into therapeutic strategies for colon malignancies. -
PI3Kγ Inhibitor
AS-041164 is a selective inhibitor of the PI3Kγ isoform, demonstrating a potent inhibitory effect with an IC50 of 70 nM. This compound exhibits significantly reduced activity against other isoforms, including PI3Kα, PI3Kβ, and PI3Kδ, with IC50 values of 240 nM, 1.45 μM, and 1.70 μM, respectively. AS-041164 is recognized for its anti-inflammatory properties and is applicable in research focused on inflammation-related pathways and diseases. -
PI3Kβ Inhibitor
MIPS-9922 is a potent and selective inhibitor of PI3Kβ, exhibiting an IC50 of 63 nM. This compound demonstrates over 30-fold higher potency for PI3Kβ compared to PI3Kδ. MIPS-9922 effectively disrupts PI3K-mediated activation of platelet glycoprotein αIIbβ3 and platelet adhesion in vitro, making it a valuable tool for studying anti-platelet and anti-thrombotic activities in research applications. -
PI3Kδ Inhibitor
Parsaclisib hydrochloride is a selective inhibitor of PI3Kδ, exhibiting an IC50 of 1 nM in the presence of 1 mM ATP. With approximately 20,000-fold selectivity over other PI3K class I isoforms, this orally active compound is valuable for investigating the biochemical pathways involved in B-cell malignancies. It is particularly useful in research focused on relapsed or refractory forms of these cancers. -
PI3Kα Inhibitor
PI3Kα-IN-4 is a selective, potent inhibitor of the phosphoinositide 3-kinase alpha (PI3Kα) with an IC50 value of 1.8 nM. This orally active compound exhibits significant antitumor activity, making it a valuable tool in cancer research. It is primarily used for investigating the role of PI3Kα in oncogenesis and therapeutic resistance. -
PI3K Inhibitor
PI3K-IN-36 is a potent inhibitor of phosphoinositide 3-kinase (PI3K), a critical enzyme involved in cell signaling pathways. This compound exhibits significant biological activity and is primarily utilized in research focused on follicular lymphoma (FL). Its effectiveness as a PI3K inhibitor makes it a valuable tool for investigating the underlying mechanisms of cancer and testing potential therapeutic strategies. -
PI3Kδ Inhibitor
Roginolisib hemifumarate is a selective inhibitor of the PI3Kδ isoform with an IC50 of 145 nM. This compound demonstrates significant selectivity across a broad panel of 278 additional kinases, making it a valuable tool for the study of signaling pathways involving PI3Kδ. Its potency and specificity facilitate research applications in cancer biology and immune modulation. -
PI3Kβ/δ Inhibitor
PI3K-IN-2 is a potent and orally bioavailable inhibitor of PI3Kβ and PI3Kδ, exhibiting IC50 values of 7.1 nM and 8.6 nM, respectively. This compound demonstrates excellent selectivity over other isoforms, such as PI3Kσ and PI3Kγ, with IC50 values of 13 nM and 190 nM. Due to its specificity and potency, PI3K-IN-2 is suitable for research applications focusing on cancer, inflammation, and other diseases associated with dysregulated PI3K signaling pathways. -
PI3K Inhibitor
PI3K-IN-18 dihydrochloride is a selective inhibitor of the PI3K p110α isoform, derived from a 4-morpholino-2-phenylquinazoline structure. This compound demonstrates significant biological activity in attenuating the PI3K signaling pathway, which plays a crucial role in cell growth, proliferation, and survival. Research applications include cancer biology, where modulation of PI3K activity can provide insights into tumor progression and therapeutic responses. -
PI4K/PI3K Inhibitor
(S)-GSK-F1 is a potent inhibitor of type III phosphatidylinositol 4-kinase α (PI4KIIIα). It demonstrates inhibitory activity against various kinases, including PI4Kα, PI4Kβ, PI4Kγ, PI3Kα, PI3Kβ, and PI3Kδ, with pIC50 values of 8.3, 6.0, 5.6, 5.6, 5.1, and 5.6, respectively. (S)-GSK-F1 has been shown to effectively inhibit hepatitis C virus (HCV) replication, making it a valuable tool for research in viral infections and signaling pathways. Its moderate pharmacokinetic profiles in rat models support its potential for in vivo studies. -
PI3K Inhibitor
(S)-PI3K-IN-2 is a selective inhibitor of phosphoinositide 3-kinase (PI3K) isoforms β and δ, exhibiting IC50 values of 0.198 μM and 0.282 μM, respectively. This compound effectively inhibits phosphorylation of AKT at serine 473 in MDA-MB-468 cancer cells, demonstrating an IC50 of 27 nM. (S)-PI3K-IN-2 is a valuable tool for investigating PI3K signaling pathways and their implications in cancer research. -
PI3Kδ Inhibitor
PI3Kδ-IN-15 is a highly selective inhibitor of the PI3Kδ isoform, demonstrating an IC50 of 0.5 nM specifically for the p110δ subunit. This compound exhibits over 30-fold greater potency against PI3Kδ compared to other isoforms including PI3Kγ, PI3Kβ, and PI3Kα. PI3Kδ-IN-15 is valuable for research applications targeting immune cell signaling and cancer biology, aiding in the exploration of therapeutic strategies for diseases associated with aberrant PI3Kδ activity. -
PI3K Inhibitor
PI3Kδ-IN-9 is a selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) with an IC50 value of 3.8 nM. It effectively modulates signaling pathways related to immune responses and inflammation. This compound is utilized in research applications focused on cancer, autoimmune diseases, and other conditions where PI3Kδ plays a critical role in cellular processes. -
PI3K Inhibitor
Vps34-IN-3 is a selective inhibitor of the VPS34 kinase, a key component of the phosphoinositide 3-kinase (PI3K) signaling pathway. This compound exhibits potent activity, making it suitable for research applications aimed at understanding lipid metabolism, autophagy, and cellular signaling processes. Its oral bioavailability enhances its utility in preclinical studies. -
PI3K Inhibitor
Nemiralisib hydrochloride is a potent and highly selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) pathway, exhibiting a pKi of 9.9. This compound demonstrates significant biological activity in modulating immune responses and is primarily utilized in research related to cancer and autoimmune diseases. Its selective inhibition of PI3Kδ makes it a valuable tool for investigating the roles of this pathway in various cellular processes and therapeutic interventions. -
BTK/PI3Kδ Inhibitor
MDVN1003 is a dual inhibitor of Bruton's tyrosine kinase (BTK) and phosphatidylinositol-3-kinase delta (PI3Kδ). This compound effectively inhibits B cell activation and blocks the phosphorylation of protein kinase B (AKT) as well as extracellular signal-regulated kinases 1 and 2 (ERK 1/2). MDVN1003 is primarily utilized in research related to non-Hodgkin’s lymphoma (NHL), offering insights into the underlying mechanisms of lymphocyte-driven malignancies. -
PI3Kδ Inhibitor
PI3Kδ-IN-8 is a selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ) with an IC50 value of 3.3 nM. It demonstrates a pronounced selectivity for PI3Kδ compared to PI3Kα, PI3Kβ, and PI3Kγ, exhibiting IC50 values of 377.2 nM, 241.6 nM, and 17.9 nM, respectively. This compound has shown significant anti-tumor activity, making it a valuable tool for research in cancer therapeutics and cellular signaling pathways involving PI3Kδ. -
PI3K Inhibitor
GSK251 is a potent and selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) isoform, exhibiting a novel binding mechanism. It demonstrates significant biological activity by effectively impeding PI3Kδ signaling pathways, which are crucial in various immune responses and hematological malignancies. GSK251 is utilized in research applications focused on understanding the role of PI3Kδ in cancer therapy and immune modulation. -
PI3Kδ Inhibitor
CHF-6523 is a selective inhibitor of PI3Kδ, which plays a crucial role in cellular signaling pathways. This compound exhibits potent biological activity in modulating immune responses and has been employed in research focused on chronic obstructive pulmonary disease (COPD). Its ability to inhibit PI3Kδ makes it a valuable tool for investigating therapeutic strategies targeting immune and inflammatory processes associated with COPD.
